Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Singapore’s GLP will do something it has never done before with this US$1.6 billion private equity fund

2018-05-11 scmp
Asia’s biggest warehouse operator, Global Logistic Properties, has established a 10 billion yuan (US$1.6 billion) private equity fund in China, in line with its strategy to pioneer a “technology-led logistics ecosystem”, according to a company statement.
GBTZY GBTZF

174
War for Asia talent pushes banks to improve plans to retain women

2018-03-21 bworldonline
YEP, THERE’S STILL plenty of long hours, hard work and heavy travel. But global investment banks in Asia that want to retain and promote women have been offering more incentives for them to return to work and stay in senior jobs — and bumping up the numbers of women in their management ranks as a result.
C.WSA GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA HSB GLSSP MS JBK TFG HCS GS.PRJ GS.PRI MS.PRI GS.PRD MS.PRK CGBBW GS.PRC GS.PRN GS.PRK GS C.WS.B C.WS.A C.PRP C.PRU RWA HSBC.PRA HSBC HBCYF C.PRS HCS.PRB C.PRL C GSC GS.PRICL C.PRJ C.PRK C.PRG GBTZY GSJ C.PRC 0005 LHHMQ C.PRPCL HSEA HSEB GJS GBTZF

174
War for Asia Talent Pushes Banks to Boost Plans to Retain Women - Bloomberg

2018-03-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
C.WSA GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA HSB GLSSP MS JBK TFG HCS GS.PRJ GS.PRI MS.PRI GS.PRD MS.PRK CGBBW GS.PRC GS.PRN GS.PRK GS C.WS.B C.WS.A C.PRP C.PRU RWA HSBC.PRA HSBC HBCYF C.PRS HCS.PRB C.PRL C GSC GS.PRICL C.PRJ C.PRK C.PRG GBTZY GSJ C.PRC 0005 LHHMQ C.PRPCL HSEA HSEB GJS GBTZF

0
Private equity-backed buyouts in Asia reach record high in 2017

2018-03-15 scmp
Asian company owners are more receptive to private equity sponsors as they are more willing to cede control of their businesses, Bain & Co report says
GBTZY GBTZF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

39m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...